Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Legacy Drug Launched in US by Licensee Spectrum

Premium

Tekmira Pharmaceuticals this week announced that Spectrum Pharmaceuticals, which licensed Tekmira's non-RNAi cancer drug Marqibo earlier this year, has launched the product in the US.

The drug is a version of the approved chemotherapeutic vincristine formulated with Tekmira's liposome technology. It is a legacy product developed by Tekmira prior to its becoming a pure-play RNAi drug developer, and was later licensed to Talon Therapeutics. Talon was acquired by Spectrum in July.

Tekmira stands to receive royalties on sales of Marqibo.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.